Literature DB >> 28132398

Modulation of antiphospholipid antibodies-induced trophoblast damage by different drugs used to prevent pregnancy morbidity associated with antiphospholipid syndrome.

Angela M Alvarez1, Norman Balcázar2, Sebastián San Martín3, Udo R Markert4, Angela P Cadavid1.   

Abstract

PROBLEM: Women with antiphospholipid antibodies (aPLs) present a risk of pregnancy morbidity (PM), vascular thrombosis (VT), or both (PM/VT). aPLs affect trophoblast function, and the aim of this study was to determine the modulation of this aPL-induced damage by different drugs. METHOD OF STUDY: IgG was obtained from women with PM and PM/VT positive to aPLs. Binding of IgG to trophoblastic cells, proliferation, mitochondrial membrane integrity, and trophoblast invasion were assessed. The effect of enoxaparin, aspirin, and aspirin-triggered lipoxin (ATL) were evaluated as well as signal transducer and activator of transcription 3 (STAT3) phosphorylation.
RESULTS: IgG from women with aPLs strongly binds to trophoblastic cells. Integrity of mitochondrial membrane was reduced, and proliferation was increased by IgG-PM/VT. Both IgG-PM and IgG-PM/VT decreased trophoblast invasion, which was restored by enoxaparin, aspirin, and ATL. IgG-PM triggered reduction in STAT3 phosphorylation.
CONCLUSION: Some drugs used to prevent aPL-induced PM modulated the alteration of trophoblast function.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  15-epi-lipoxin A4; STAT3; placental development; pregnancy morbidity

Mesh:

Substances:

Year:  2017        PMID: 28132398     DOI: 10.1111/aji.12634

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  7 in total

1.  The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study.

Authors:  Meital Shlomo; Rafael Gorodischer; Sharon Daniel; Arnon Wiznitzer; Ilan Matok; Boris Fishman; Gideon Koren; Amalia Levy
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Maternal Thrombophilia and Recurrent Miscarriage - Is There Evidence That Heparin is Indicated as Prophylaxis against Recurrence?

Authors:  Ana-Luisa Stefanski; Christoph Specker; Rebecca Fischer-Betz; Wolfgang Henrich; Ekkehard Schleussner; Thomas Dörner
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-03-21       Impact factor: 2.915

3.  Obstetric Antiphospholipid Syndrome: An Approach from Glycans of the Immunoglobulin G.

Authors:  Angela María Alvarez; Alejandra Maria Gomez-Gutierrez; Julio César Bueno-Sánchez; Carolina Rúa-Molina; Angela Patricia Cadavid
Journal:  J Hum Reprod Sci       Date:  2021-03-30

4.  Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome.

Authors:  Manuela Velásquez; Luisa F Peláez; Mauricio Rojas; Raúl Narváez-Sánchez; Jesús A Velásquez; Carlos Escudero; Sebastián San Martín; Ángela P Cadavid
Journal:  Front Physiol       Date:  2021-12-02       Impact factor: 4.566

5.  Antiphospholipid Antibodies From Women With Pregnancy Morbidity and Vascular Thrombosis Induce Endothelial Mitochondrial Dysfunction, mTOR Activation, and Autophagy.

Authors:  Carlos M Rodríguez; Manuela Velásquez-Berrío; Carolina Rúa; Marta Viana; Vikki M Abrahams; Angela P Cadavid; Angela M Alvarez
Journal:  Front Physiol       Date:  2021-11-29       Impact factor: 4.566

6.  Oxidative stress in endothelial cells induced by the serum of women with different clinical manifestations of the antiphospholipid syndrome

Authors:  Manuela Velásquez; Manuel Alejandro Granada; Juan Camilo Galvis; Ángela María Álvarez; Ángela Cadavid
Journal:  Biomedica       Date:  2019-12-01       Impact factor: 0.935

Review 7.  Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology.

Authors:  Małgorzata Szczuko; Joanna Palma; Justyna Kikut; Natalia Komorniak; Maciej Ziętek
Journal:  Inflamm Res       Date:  2020-06-02       Impact factor: 6.986

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.